STOCK TITAN

integ - integ STOCK NEWS

Welcome to our dedicated news page for integ (Ticker: integ), a resource for investors and traders seeking the latest updates and insights on integ.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect integ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of integ's position in the market.

Rhea-AI Summary
Integrum (INTEG) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024, at 14:00 CEST. CEO Rickard Brånemark, CFO Jörgen Svanström, and US President Jeffrey Zanni will present in English. The report will be available at integrum.se, and the webcast can be accessed at finwire.tv.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
earnings
-
Rhea-AI Summary
Integrum (INTEG) announces the sale of OPRA Implant Systems worth SEK 3.5 million to the Center of Excellence in Kyiv, Ukraine, following the successful establishment of the center in December 2023. The company has trained and certified two senior surgeons to perform surgeries on amputees using the innovative implant system. The purchase aims to ensure continuous access to the OPRA Implant System. The disclosure contains information pursuant to the EU Market Abuse Regulation. The CEO, Rickard Brånemark, highlighted the urgent need for amputee care in Ukraine, especially following the Russian invasion. The company's implant system, which attaches directly to the skeleton, provides the best care for many amputees. The PR also includes contact information for more details and the Certified Adviser for Integrum. The press release can be found at the link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
-
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) establishes a Center of Excellence in Kyiv to spearhead orthopedic treatment using OPRA™ Implant System for individuals who have suffered limb loss, addressing the increased need for amputee care in Ukraine following the Russian invasion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data. The company aims to broaden the regulatory approval in the US for the OPRA Implant System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
clinical trial
-
Rhea-AI Summary
INTEG B - Integrum (publ) Expects Higher Q2 Revenue, Operating Profit, and Cash Flow, Preliminary Figures Show 36.2% Revenue Increase and 611.1% Operating Profit Surge
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
-
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) announces full funding from the US Department of Defense for a clinical study of OPRA™ Implant System on up to 30 patients with transtibial amputations. The study will be conducted at the Walter Reed National Military Medical Center. The FDA-approved study will provide crucial data for future regulatory processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
clinical trial
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) expects Q2 revenue, operating profit, and cash flow to exceed market expectations. Revenue expected at 27.5 MSEK, a 36.2% increase from last year. Operating profit expected at 6.4 MSEK, with an increase attributed to activity and improved cost structure. Cash flow expected at 3.4 MSEK. Complete results to be presented in the quarterly report for August - October 2023 on December 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
none
-
Rhea-AI Summary
Integrum's OPRA™ Implant system receives FDA approval for a clinical study on below-knee amputations in the US. The study will be conducted by the Walter Reed National Military Medical Center and is crucial for future approval of the system. CEO Rickard Brånemark considers this a significant milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
clinical trial fda approval
-
News
Rhea-AI Summary
Integrum announces entry into Turkish market with OPRA™ Implant system in collaboration with Medikon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.82%
Tags
none
integ

Nasdaq:INTEG

INTEG Rankings

INTEG Stock Data